How it works:
Pegfilgrastim is a pegylated form of filgrastim with extended half-life. It stimulates the bone marrow to produce neutrophils and is effective in preventing severe neutropenia and its complications during chemotherapy.
Recommended for:
Patients undergoing myelosuppressive chemotherapy
Those at high risk of febrile neutropenia
Oncology patients with compromised immune function
To reduce hospitalisation due to infections
Prevention of chemotherapy-induced neutropenia and febrile neutropenia in patients with malignant diseases
PEG GRAFEEL is administered subcutaneously once per chemotherapy cycle, typically 24 hours after the end of chemotherapy. Dosage and frequency are determined individually by the treating physician.
Contraindications:
Hypersensitivity to pegfilgrastim or filgrastim
Sickle cell anaemia
Paediatric use (in some cases)
Active bone marrow malignancies unrelated to chemotherapy
Side effects:
Bone and muscle pain
Headache
Elevated white blood cell count
Injection site reactions
Nausea
Rare: allergic reactions, splenomegaly
